The largest B2B cannabis industry event in New Jersey – NECANN’s New Jersey Cannabis Convention – returns to Atlantic City on September 8-9, 2023. Now in its 4th year, the event, which is part of the largest cannabis and hemp convention series in the world, continues to grow as the New Jersey cannabis market develops. It comes more than a year after the state legalized the sale of recreational marijuana, which led to the April 2023 opening of the first licensed recreational marijuana dispensary in Atlantic City (https://ibn.fm/t15j2).

With such stores finally opening and the number of licenses rapidly increasing, the number of ancillary businesses, entrepreneurs, investors, cultivators, medical dispensaries, license holders, and suppliers, is increasing by the day. Conveniently, NECANN’s New Jersey Cannabis Convention is designed for this category of budding industry players and entrants, among others. The event represents everything that touches cannabis and promises to be the perfect setting for attendees to learn about the industry.

“There’s everything here that you could possibly learn about the cannabis industry. Everything from grow lights, payment processors, banking, [and] accounting. If you are looking to start any type of cannabis business, you can come to NECANN and learn whatever you are trying to learn,” said Brian O’Connor of Paybotic, a payment processor that enables cannabis businesses to transact, in a video recapping the 2021 event (https://ibn.fm/5npQw).

What makes the New Jersey Cannabis Convention particularly appealing to startups is the fact that it is an opportunity to meet similar sprouting businesses. Even so, the event is equally suited for exhibitors drawn from every niche within the cannabis industry. Attracting thousands of cultivators, industry professionals, educators, and advocates, from hundreds of local and national companies, the New Jersey Cannabis Convention promises a lot of foot traffic, much to the advantage of vendors and businesses showcasing their products. In fact, exhibitors who were part of previous editions of the event have lauded its role in bringing them closer to investors and potential business partners. The 2023 event will be no different, so reserve your exhibit space today.

For attendees in pursuit of knowledge, there’s more! The activity-packed two-day event features learnings from expert speakers delivered through dozens of planned sessions. Moreover, there are plenty of networking opportunities. The New Jersey Cannabis Convention is the perfect setting to learn, meet, and network. So do not miss it – register today.

For more information, please visit https://ibn.fm/IWEr5

• SuperCom, through its fully-owned subsidiary, Leaders in Community Alternatives (“LCA”), just closed a multi-million dollar contract in California that will run until 2026
• The contract marks another substantial achievement for SuperCom, building on a track record of securing numerous electronic monitoring contracts in the U.S. and Europe
• The company’s management notes how well it is positioned to help the electronic monitoring industry move into the future

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity security solutions offering advanced safety, identification, and security products and solutions to governments, just closed a multi-million dollar contract in California. The contract, secured through SuperCom’s fully-owned subsidiary, Leaders in Community Alternatives (“LCA”), will see the company provide alcohol monitoring technologies and services in the state and will run until 2026, including an initial 3-year period with the potential for future extensions (https://ibn.fm/g8Kuh).

“Our reputation for providing reliable and high-quality electronic monitoring services was pivotal in securing the contract,” noted Ordan Trabelsi, SuperCom’s President and CEO. “We are proud to have been chosen once again to support California’s criminal justice system,” he added.

The contract marks another substantial achievement for SuperCom, building on a track record of securing numerous electronic monitoring (“EM”) contracts in the U.S. and Europe. Thus far, through its EM platforms, the company has helped governments and national agencies design, launch, and operate numerous EM programs worldwide (https://ibn.fm/fauLo).

SuperCom has also made a name for itself in the cybersecurity space. Through two key acquisitions – Prevision Ltd. and Safend Ltd., the company has positioned itself as an international provider of cutting-edge endpoint data protection, encryption, and comprehensive device and port control.

The electronics monitoring solutions market is expected to hit $2.1 billion in 2026, while the global cybersecurity market is expected to be valued at $266.2 billion by 2027.

“As we move forward, we remain committed to fostering strong partnerships, driving technological advancements, and delivering top-tier solutions that address the unique challenges faced by the criminal justice system,” noted Ordan.

The company’s management believes these moves position it to help lead the electronic monitoring industry into the future. The California contract validates SuperCom’s current market position while affirming its commitment to delivering high-quality services and cutting-edge monitoring solutions to government agencies.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Eloro Resources recently published a new corporate update detailing ongoing developments within the company
• Eloro is continuing to work on the upcoming publication of its inaugural NI 43-101 compliant mineral resource estimate report, which will provide the market with more granular information related to the commercial viability of the Iska Iska project
• The company has recently carried out a variety of further studies within the site, including looking into the viability of ‘ore sorting’, a determinant of overall resource extraction efficiency

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mining company focused on developing its potential world-class Iska Iska silver-tin polymetallic property located in the Potosi Department in southern Bolivia, recently provided investors and corporate stakeholders with an overview of the company’s ongoing developments. With the company having engaged in exhaustive exploratory drilling and analysis activities dating back to the inception of the Iska Iska project, Eloro Resources are now embarked on the process of finalizing the release of their initial mineral resource estimate (“MRE”) report, which will seek to provide the market with further granularity as to the Iska Iska property’s viability as a commercial mining operation going forward (https://ibn.fm/qUmUv).

Previously exploited by artisanal miners in the early 1960s, repeated surveys of Eloro’s Iska Iska and Mina Casiterita properties – the latter situated to Iska Iska’s immediate southwest, have outlined the appearance of an extensive, near surface, magnetic intrusive body spread across the two sites. These findings have been further complemented by an extensive program of exploratory drill work across the sites- dating back to early 2021 and amounting to a cumulative 85,000 meters of diamond drilling across 122 individual holes. Recent conclusions drawn from this drill work have driven the mining company to vastly increase their initial projections related to the potential scale of the deposit at hand; Eloro’s most recent model now suggests that the company could potentially have access to a high-grade deposit (defined as having potential deposits of > 90g AG eq/t) measuring 800 meters wide and over 1,100 meters in depth.

In addition to its drill work, Eloro Resources have sought to measure the potential refining efficiency of the site, factors which will ultimately influence the commercial viability of a site should mining activity formally commence.  Preliminary tests carried out at TOMRA in Germany have found the mineralization at Iska Iska to be amenable to ‘ore sorting’; in effect, the tests have found that at least 40 percent of the waste within the Iska Iska site’s Polymetallic domain and up to 80 percent of the waste in the Tin domain may be removed prior to submitting the ore for further refining. In effect, this will increase the concentrator feed grades, thus reducing future operating costs and significantly decreasing the cut-off grades (“COG”) for the upcoming mineral resource estimate report.

In the coming weeks, Eloro Resources expect to publish their inaugural NI 43-101 compliant mineral resource estimate relating to the Santa Barbara High-Grade Zone, situated within the Iska Iska property site. Meanwhile, however, the company has continued its exploratory mining work spread across a wide array of areas within the Iska Iska and Mina Casiterita properties. Initial diamond drilling and geophysical surveys verifying the potential of a major tin porphyry located to the south of Iska Iska and southwest of Casiterita have been carried out, with results currently pending. Simultaneously, recent drill intersections, inverse magnetic models and deep drill intersections have opened up the possibility of a major tin porphyry beneath the Porco area to the south and extending into Mina Casiterita.

With Eloro Resources’ initial MRE report soon to be published – followed shortly thereafter by a preliminary economic assessment (“PEA”) report – Eloro Resources continues to march resolutely on towards an eventual future entailing commercial mining operations within its flagship Iska Iska site.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• GEMXX Corporation is a unique vertically integrated jewelry producer, focused on managing costs in-house by mining its own gold and gemstones via its Canadian mine resources for its many jewelry products
• GEMXX has been engaged this year in bringing one of its British Columbia gold ore sites up to full production
• The company recently announced the encouraging results of gold ore processed from surface materials stockpiled during site construction, amounting to 0.86 ounces per 100 cubic yards
• GEMXX will add the gold processed from the site to fossilized, iridescent Ammolite gemstones from its Alberta resources, as the materials for its jewelry

Mine-to-market global jewelry producer GEMXX (OTC: GEMZ) is increasing its capacity for gold ore processing at one of the company’s Canadian assets, enthusiastic over the better-than-expected amount of ore produced from stockpiled surface material.

GEMXX’s Snow Creek Mine property in British Columbia completed site preparation for gold processing last year and mobilized equipment in May to begin bringing the property into full production (https://ibn.fm/ah7a9). GEMXX reported the first production of gold from the site on Aug. 15 as ore collected from a 4,500-cubic-yard sample during construction of the facility was “cleaned out.”

The operation yielded 38.73 ounces of gold, amounting to 0.86 ounces per 100 cubic yards, according to the company’s statement (https://ibn.fm/JNtFk).

“These results are a promising start to what is anticipated to be a highly lucrative first year of gold mining,” Ian McClintock, the president of GEMXX’s exploration partner Crazy Horse Mining Inc., stated in the news release.

GEMXX is anticipating that gold ore from the 498-acre site, together with ammolite from its Alberta resources, will bolster the company’s long-term plans to expand its jewelry production and “de-risk revenues,” CEO Jay Maull added.

GEMXX has also acquired a second gold resource in British Columbia — the 240-acre Rosella Creek project. Initial testing at the two sites has led the company to estimate the properties could yield over 100,000 ounces of easily recoverable gold.

GEMXX has scheduled an S-K 1300-compliant Resource Report to be completed this summer to provide verification of its estimate.

“The acquisition of the Snow Creek and Rosella Creek gold asset … complements our ammolite production with the world’s most sought-after commodity. This will provide GEMXX with a significant reduction in the cost of goods for our entire gold jewelry product line and will bring the Company one step closer to our goal of becoming vertically integrated,” Maull stated. 

The company has contracted with publicity agencies this year to increase brand awareness of its operations, and has begun fund-raising efforts for its Reg A offering, which is fully qualified for $6 million at 40 cents per share (https://ibn.fm/2fBx0).

Ammolite, the gemstone that has been the centerpiece of GEMXX’s jewelry production, is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses. Alberta is the only place in the world where the gem is mined commercially, thanks apparently to historical conditions unusual to the region, since only select ammonite fossils result in ammolites, according to research published by the University of Alberta (https://ibn.fm/hQmfh).

Ammolites were only formally recognized as a gemstone in 1981, but are now valued for their iridescent colors, which are a result of alternating layers of the mineral aragonite and the protein in the ammonites’ shells, the article states.

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV
• Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat
• The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results

As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

Renovaro’s oncology platform is now at the forefront of the company’s development activities – primarily focused on pancreatic cancer. The company also plans to include other solid tumors with short life expectancy in the first human Phase I/IIa studies that are on track for mid-2024. Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat.

The company’s novel technology uses cell and gene therapies to promote a renewed immune response against solid tumors. Dr. Anahid Jewett, a renowned cancer researcher at UCLA, independently conducted Renovaro’s two humanized mouse model tests using the company’s novel dendritic cell-based therapy. These important findings were presented at two scientific conferences and were the foundation supporting a pre-IND submission to the US Food and Drug Administration (“FDA”). Notably, the findings from Dr. Jewett’s study consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro’s current product development pipeline includes the following:

• RENB-DC11 – an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors
• RENB-HV12 – an engineered allogeneic T-Cell vaccine and HIV vaccine candidate with IND submission is expected in the second half of 2024
• RENB-HV21 – another potential therapy for HIV that shows promising preliminary results, Renovaro holds an exclusive license and has completed the Pre-IND submission with potential IND submission and human trials expected in 2024
• RENB-HV01 – Caring Cross, a non-profit corporation, has entered into a sublicense to share profits if the product is commercialized, which has shown that proprietary CAR-T cells cure HIV in mouse models
• RENB-HB01 – a therapeutic approach that aims to eliminate HBV rapidly, with a two to three-dose treatment regimen

Renovaro recently announced the execution of a binding, exclusive letter of intent (“LOI”) with GEDi Cube, a cutting-edge health AI company. Renovaro’s officials are confident that joining forces with GEDi Cube will help enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.

“Our advanced cell, gene, and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms,” said Dr. Mark Dybul, CEO of Renovaro (https://ibn.fm/L54YI). “I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• SuperCom recently released its second quarter and first half 2023 results for the period ended June 30, 2023
• Financial highlights included a 141% YoY increase in quarterly revenue and a 126% YoY increase in half-year revenue to $7.7 million and $14.1 million, respectively
• The company reported a 106% increase in trailing-twelve-month revenue to $25.5 million from $12.4 million
• SuperCom provided business highlights, documenting its recently awarded contracts and projects in Europe (Romania, Finland, and Iceland) as well as in the US
• President and CEO Ordan Trabelsi credits the company’s investments in research and development as well as sales and marketing for its ability to land global opportunities and displace incumbents

SuperCom (NASDAQ: SPCB), a global provider of traditional and digital identity solutions, providing advanced safety, identification, Internet of Things (“IoT”), connectivity, and security solutions to governments and private and public organizations globally, recently released its financial and operating results for the three and six months ended June 30, 2023, as well as financial highlights for the trailing-twelve-month period (https://ibn.fm/7seN6).

“We are excited to announce breakthrough performance for Q2 2023, where we outperformed expectations on multiple fronts. Our efforts have catapulted us to new heights, realizing a substantial 141% year-over-year (“YoY”) revenue growth, as well as record-breaking quarterly revenue of $7.7 million and non-GAAP earnings per share (“EPS”) of $0.07. Furthermore, this quarter closes an exceptional trailing twelve-month period boasting $25.5 million in revenue and $2.5 million in EBITDA, underscoring our focus on sustained growth and profitability,” said SuperCom President and CEO Ordan Trabelsi.

SuperCom celebrated a fourth consecutive quarter of high YoY revenue growth, reporting a 141% increase in revenue to a five-year record of $7.7 million, up from $3.2 million recorded in Q2 2022. Its gross profit for this reporting period grew 77% to $2.3 million from $1.3 million. The company also ended the quarter with working capital of $21.2 million. Furthermore, results from the just-ended quarter contributed to half-year revenue of $14.1 million for the first half of fiscal 2023, a 126% YoY increase from $6.3 million, as well as a gross profit of $3.9 million, representing an increase YoY of 47% from $2.6 million.

Other notable highlights included a 106% YoY increase in trailing twelve-month revenue to $25.5 million from $12.4 million. In his address to shareholders during a conference call held July 31, 2023, Trabelsi attributed this growth to the IoT division, the company’s “primary growth engine” (https://ibn.fm/3QY0O). Putting things into perspective, Trabelsi said, “While the global electronic monitoring market grows at approximately 11% per year, SuperCom’s IoT revenue achieved over 100% growth in the past twelve months, outpacing the global market growth by over a multiple of 10x. This growth is a testament to the fact that the market prefers our solution over alternatives.”

SuperCom also provided business updates, discussing the recently awarded contracts and projects worldwide. The company, the press release stated, is well on track with the implementation of a $33 million national electronic monitoring (“EM”) project in Romania, which covers domestic violence protection, GPS tracking of offenders, and home detection monitoring and uses the company’s PureSecurity EM Suite. 

In Europe, the company has deployed the PureSecurity EM Suite in Finland as part of a national project with the national government, covering programs such as GPS tracking, house arrest, and inmate monitoring. The project, launched in Q1 2023, is valued at $3.6 million. SuperCom has also launched a new project in Iceland.

Moreover, the company’s wholly-owned subsidiary, LCA, won a $4.25 million contract to provide adult reentry services in a county in Northern California, US. The project, which began in Q1 2023 and expanded LCA’s existing EM and day reporting services to include community-based and jail-based sites, is actively servicing clients and generating recurring revenue, according to the company.

SuperCom also celebrated other milestones, including the completion of the development and multiple successful deployments of PureProtect, its life-saving domestic violence monitoring solution, and the launch in various regions of the US of PureOne, its best-in-class all-in-one GPS tracking ankle-bracelet monitoring solution. SuperCom is prioritizing the expansion of PureOne into new markets and geographies.

“SuperCom’s proprietary technology has been a game-changer in competitive tenders worldwide, enabling us to displace incumbent vendors and make a significant impact on public safety around the globe. Our steadfast commitment to technology superiority is evident in our recent incorporation of AI capabilities into our products, along with the continuous launch of innovations such as the recent PureProtect and PureOne solutions. These efforts propel our business growth and solidify our path toward industry leadership,” Trabelsi explained.

According to Trabelsi, the company’s investments in research and development as well as sales and marketing have paved the way for global opportunities, enabling it to deliver exceptional value to its growing list of clients while turbocharging its resolve to meet its long-term objectives.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

Counterculture retail professionals, business executives, researchers, and industry leaders, are invited to attend Alternative Products Expo to be held in Las Vegas from September 14-16, 2023.  Dedicated to promoting creativity, the much-awaited event will be focused on eco-friendly solutions and alternative products. The Expo is set to engage audiences with a wide range of unique and sustainable products that signify the latest trends and technological advancements.

The Expo aims to empower participants to make informed buying decisions while contributing to a progressive, more sustainable future. By showcasing a wide range of ethically sourced and environmentally friendly alternatives, the Expo is about creating a socially responsible community that aligns with technological innovations and sustainable best practices.

Alternative Products Expo will feature a diverse group of eco-conscious entrepreneurs, business leaders, and innovators, providing insights into the intricacies of sustainable products while enlightening attendees about market potential and current opportunities.

Innovation meets Sustainability

Alternative Products Expo promises to provide an immersive experience through engaging workshops, enlightening exhibits, and best-in-class networking opportunities. Attendees will get a unique opportunity to meet industry leaders and learn from their experience spanning a range of industries, including renewable energy, vaping, beverages, and more.

Experience the blend of creativity and sustainability as top industry leaders showcase their collections. From fair trade practices to upcycled materials, the Expo will reveal unique, game-changing ideas that drive innovation in style. Business owners will exhibit their newest products, challenging the boundaries and redefining innovation.

Thought-provoking seminars and workshops will enable attendees to learn about the latest innovations in the alternative products industry, from zero-waste packaging to renewable energy solutions.

To learn more, please visit https://ibn.fm/21jUz

GolfLync, the innovative social media networking platform designed exclusively for golf enthusiasts, is ushering in a new era for the golfing community with its groundbreaking feature, Virtual Golf Clubs(TM) (“VGC”). This cutting-edge addition to the app empowers golfers to connect, share experiences, and create thriving golfing communities, making GolfLync the go-to destination for passionate golfers across the United States.

The Evolution of Golfing Communities

Golf has always been a sport that fosters camaraderie and social connections. Traditionally, golfers would come together at local golf courses and clubs, forming tight-knit communities based on their love for the game. With the rise of social media, golfers began exploring digital spaces to extend their connections and share their golfing journeys.

Enter GolfLync – a game-changing platform that took the concept of golfing communities to the next level. Formerly known as Groups, the newly rebranded Virtual Golf Clubs(TM) feature elevates the experience by offering a more focused and immersive golfing environment.

Discovering Local Golf Communities and Clubs

Virtual Golf Clubs(TM) now allow members to effortlessly find local golf communities and public golf clubs in their area. Whether a golfer is new to a city, seeking a fresh community, or eager to explore new golfing opportunities, VGC offers an easy-to-use interface that connects users with like-minded individuals sharing the same passion for the sport.

The Rise of GolfLync – The Leading Social Media Platform for Golfers

GolfLync’s impact on the golfing community has been nothing short of extraordinary. With thousands of golfers joining the platform from all states and major cities in America, GolfLync has cemented its position as the leading social media application exclusively tailored for golfers.

GolfLync founders realized this early on and have recently trademarked the Virtual Golf Clubs(TM) name and rapidly started expanding VGC features, including feeds allowing club members to post pictures, videos and score cards, multiple Tee Times that notify other members of the club to join, and integrated chat between all members of the VGC.

The platform’s remarkable growth has even caught the attention of influencers from other social media platforms. Influencers are now transitioning to GolfLync to become Virtual Golf Clubs(TM) hosts, creating an environment where golfers can access a higher-quality golf-focused experience, with exclusive insights and tips from their favorite influencers.

Creating Engaged Golfing Communities

At the heart of Virtual Golf Clubs(TM) is the promise of vibrant and thriving golfing communities. Users can seamlessly connect with fellow golf enthusiasts, share insights, and plan exciting golf outings together. Whether golfers are seeking casual rounds, competitive matches, or even new golfing buddies, VGC ensures they find the perfect match for their golfing adventures.

An All-in-One Platform

GolfLync’s holistic approach to social golfing sets it apart from traditional social media applications. The platform combines advanced social media-styled feeds with intelligent algorithms that recommend relevant Virtual Golf Clubs(TM) based on users’ locations, interests, and golfing proficiency, including factors such as handicap and preferred playing style.

An Exciting Future for GolfLync

As GolfLync continues to revolutionize the social golfing experience, the platform’s dedication to innovation and user satisfaction remains unwavering. With the launch of Virtual Golf Clubs(TM), GolfLync has solidified its position as a pioneering social media platform exclusively designed to cater to the diverse needs of golfers.

The future of golfing communities is here, and it’s called Virtual Golf Clubs(TM). Golf enthusiasts and investors alike are invited to explore the world of GolfLync and be part of this exciting golfing revolution. For more information about GolfLync and its cutting-edge offerings, visit the official website at www.GolfLync.com and experience golfing like never before.

For more information about GolfLync, visit GolfLync, download the app, and connect with community on Facebook, X and LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix
• The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan and plans to begin the same in China in 2023
• UPNEEQ(R) has strong U.S. intellectual property protection, with patents extending to 2039
• RVL Pharmaceuticals launched its prescription ecommerce platform, Elevate, in July 2023, allowing providers and patients to purchase RVL products and sign up for auto-refills
• UPNEEQ(R) consumer awareness remains very low among U.S. adult women, presenting a major opportunity to increase awareness and demand through Direct-to-Consumer efforts

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults.

UPNEEQ(R) (RVL-1201) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (FDA) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ(R) in September 2020 to a limited number of eye care professionals, with commercial operations expanded in 2021 among ophthalmology, optometry, and oculoplastic specialties.

In February 2022, UPNEEQ(R) was launched into the medical aesthetics market in the United States. Patients can purchase UPNEEQ(R) from eye care or medical aesthetic professionals, or through RVL Pharmacy LLC, the company’s wholly owned pharmacy. The company plans to promote UPNEEQ(R) to people with acquired ptosis and those who are bothered by low-lying lids. RVL Pharmaceuticals believes there is a significant commercial opportunity for UPNEEQ(R), given the meaningful unmet need for a non-invasive treatment across millions of acquired-ptosis patients in the United States. The company’s near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated aesthetics sales force while continuing to support ongoing utilization and expanded penetration of UPNEEQ(R) in ocular medicine markets.

RVL Pharmaceuticals continues to raise patient and physician awareness of acquired ptosis and UPNEEQ(R) through medical conferences, HCP and DTC advertising, social media (e.g., Facebook and Instagram), and marketing partnerships.

The company is incorporated in Ireland and headquartered in Bridgewater, New Jersey.

UPNEEQ(R)

UPNEEQ(R) is an oxymetazoline hydrochloride ophthalmic solution for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults. It is the first and only FDA-approved ophthalmic solution for this indication.

The once-daily UPNEEQ(R) eye drop has been shown in clinical trials to result in an average one-millimeter lift of the upper eyelid, and to improve superior visual field in patients with a functional deficit. Patients’ eyelids demonstrate lift in as little as five minutes post dose, with the lift effect lasting as long as eight hours. The preservative-free solution is safe and well-tolerated. Trials demonstrated side effects similar to those of placebo.

The active ingredient in UPNEEQ(R) is oxymetazoline 0.1%, a direct-acting α-adrenergic receptor agonist that targets receptors in the Müller’s muscle, which causes the muscle to contract and lift the upper eyelid. UPNEEQ(R) delivers eye-opening results for patients along the entire spectrum of age and condition severity.

UPNEEQ’s health care provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

The target patient population comprises adults with droopy or low-lying eyelids, the majority of whom are female. While the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.

Market Opportunity

A survey of eye care providers and medical aesthetics specialists revealed that they believe that approximately half of adult patients visiting their practices are affected by droopy or low-lying eyelids. Further, the company estimates that approximately 60% of adult women self-identify as having some degree of droopy or low-lying eyelids, and a majority of those women indicate that they are bothered by the position of their eyelids.

The global medical aesthetics market is expected to reach a value of $18 billion in 2027, rising at a compound annual growth rate of over 10%, with North America representing the largest share of the global market. Similarly, the global eye care market is expected to reach a value of $86 billion by 2026, rising at a compound annual growth rate of over 6%. An estimated 100 million adults visit an eye care provider each year in the United States alone.

RVL Pharmaceuticals believes the growth in medical aesthetics and eye care markets will be driven by an aging population and increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time. Other contributing factors include rising disposable income globally and in the U.S.; growing awareness, utilization, and acceptance of elective or minimally invasive and non-invasive interventions; and continued innovation and improved accessibility to treatments due to an increase in the number of physicians who offer eye care and medical aesthetics services.

Management Team

Brian Markison is Chairman of the Board and Chief Executive Officer of RVL Pharmaceuticals. He has more than 30 years of operational, marketing, commercial development, and sales experience with international pharmaceutical companies. He previously served as the President and CEO of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company. Before that he was Chairman and CEO of King Pharmaceuticals Inc. He also held various senior leadership positions at Bristol-Myers Squibb. He received a bachelor’s degree from Iona College.

James Schaub is Executive Vice President and Chief Operating Officer of RVL Pharmaceuticals. Prior to that he served as COO of Trigen Laboratories. He previously was Vice President, M&A of Fougera Pharmaceuticals. Before that he spent five years with King Pharmaceuticals. Mr. Schaub holds a bachelor’s degree in economics from Middlebury College and an M.B.A. from Rutgers Business School.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

• Combination of advanced AI machine learning technology and proven immunotherapy technology seen as “future of medicine”
• Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically
• Potential applications against variety of cancers

The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing a potentially transformative step in the fight against cancer. Considering Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy, that has already demonstrated significant results with its technology against pancreatic cancer, and GEDi Cube, with an AI, machine learning technology that has validated earlier diagnoses of lung cancer in humans, already expanding to 12 additional cancers, combining the companies is being seen as pointing to the future of medicine.

The technology multiplier effect of combining powerful advanced AI processing and machine learning capabilities, and proven leading-edge immunotherapy technology, lifts the fight against cancer to a new level. The success that both companies have shown with their innovative developments is expected to expand synergistically.

Regarding Renovaro, “Dr. Anahid Jewett is a leading cancer immunotherapy researcher at UCLA who has conducted independent, pivotal studies with Renovaro’s technology in different animal models. She has consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response” (https://ibn.fm/sZfWp).

Craig Rhodes, CEO of GEDi Cube International Ltd. “GEDi Cube’s remarkably innovative technology developed over nearly a decade has already validated earlier diagnoses of lung cancer in humans at a leading university hospital and created the technology for 12 additional cancers, including pancreatic and breast cancer.”

Regarding the two companies joining forces, Dr. Mark Dybul, Renovaro CEO, said. “Our advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms. I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB